dc.contributor.author |
Kaufman, Jacob M |
|
dc.contributor.author |
Amann, Joseph M |
|
dc.contributor.author |
Park, Kyungho |
|
dc.contributor.author |
Arasada, Rajeswara Rao |
|
dc.contributor.author |
Li, Haotian |
|
dc.contributor.author |
Shyr, Yu |
|
dc.contributor.author |
Carbone, David P |
|
dc.date.accessioned |
2018-08-02T20:36:25Z |
|
dc.date.available |
2018-08-02T20:36:25Z |
|
dc.date.issued |
2014-06 |
|
dc.identifier |
S1556-0864(15)30302-6 |
|
dc.identifier.issn |
1556-0864 |
|
dc.identifier.issn |
1556-1380 |
|
dc.identifier.uri |
https://hdl.handle.net/10161/17310 |
|
dc.description.abstract |
Inactivation of serine/threonine kinase 11 (STK11 or LKB1) is common in lung cancer,
and understanding the pathways and phenotypes altered as a consequence will aid the
development of targeted therapeutic strategies. Gene and protein expressions in a
murine model of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras)-mutant
lung cancer have been studied to gain insight into the biology of these tumors. However,
the molecular consequences of LKB1 loss in human lung cancer have not been fully characterized.We
studied gene expression profiles associated with LKB1 loss in resected lung adenocarcinomas,
non-small-cell lung cancer cell lines, and murine tumors. The biological significance
of dysregulated genes was interpreted using gene set enrichment and transcription
factor analyses and also by integration with somatic mutations and proteomic data.Loss
of LKB1 is associated with consistent gene expression changes in resected human lung
cancers and cell lines that differ substantially from the mouse model. Our analysis
implicates novel biological features associated with LKB1 loss, including altered
mitochondrial metabolism, activation of the nuclear respiratory factor 2 (NRF2) transcription
factor by kelch-like ECH-associated protein 1 (KEAP1) mutations, and attenuation of
the phosphatidylinositiol 3-kinase and v-akt murine thymoma viral oncogene homolog
(PI3K/AKT) pathway. Furthermore, we derived a 16-gene classifier that accurately predicts
LKB1 mutations and loss by nonmutational mechanisms. In vitro, transduction of LKB1
into LKB1-mutant cell lines results in attenuation of this signature.Loss of LKB1
defines a subset of lung adenocarcinomas associated with characteristic molecular
phenotypes and distinctive gene expression features. Studying these effects may improve
our understanding of the biology of these tumors and lead to the identification of
targeted treatment strategies.
|
|
dc.language |
eng |
|
dc.publisher |
Elsevier BV |
|
dc.relation.ispartof |
Journal of thoracic oncology : official publication of the International Association
for the Study of Lung Cancer
|
|
dc.relation.isversionof |
10.1097/jto.0000000000000173 |
|
dc.subject |
Cell Line, Tumor |
|
dc.subject |
Mitochondria |
|
dc.subject |
Animals |
|
dc.subject |
Humans |
|
dc.subject |
Mice |
|
dc.subject |
Adenocarcinoma |
|
dc.subject |
Carcinoma, Non-Small-Cell Lung |
|
dc.subject |
Lung Neoplasms |
|
dc.subject |
ras Proteins |
|
dc.subject |
Protein-Serine-Threonine Kinases |
|
dc.subject |
Receptor, Epidermal Growth Factor |
|
dc.subject |
Intracellular Signaling Peptides and Proteins |
|
dc.subject |
Adaptor Proteins, Signal Transducing |
|
dc.subject |
Cytoskeletal Proteins |
|
dc.subject |
Proto-Oncogene Proteins |
|
dc.subject |
RNA, Messenger |
|
dc.subject |
Signal Transduction |
|
dc.subject |
Phosphorylation |
|
dc.subject |
Mutation |
|
dc.subject |
Multigene Family |
|
dc.subject |
Tumor Suppressor Protein p53 |
|
dc.subject |
Proto-Oncogene Proteins p21(ras) |
|
dc.subject |
Proto-Oncogene Proteins c-akt |
|
dc.subject |
NF-E2-Related Factor 2 |
|
dc.subject |
GA-Binding Protein Transcription Factor |
|
dc.subject |
AMP-Activated Protein Kinases |
|
dc.subject |
Phosphatidylinositol 3-Kinase |
|
dc.subject |
Transcriptome |
|
dc.subject |
Ataxia Telangiectasia Mutated Proteins |
|
dc.subject |
Kelch-Like ECH-Associated Protein 1 |
|
dc.title |
LKB1 Loss induces characteristic patterns of gene expression in human tumors associated
with NRF2 activation and attenuation of PI3K-AKT.
|
|
dc.type |
Journal article |
|
duke.contributor.id |
Kaufman, Jacob M|0684401 |
|
dc.date.updated |
2018-08-02T20:36:20Z |
|
pubs.begin-page |
794 |
|
pubs.end-page |
804 |
|
pubs.issue |
6 |
|
pubs.organisational-group |
Staff |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Medicine, Medical Oncology |
|
pubs.organisational-group |
Medicine |
|
pubs.organisational-group |
Clinical Science Departments |
|
pubs.organisational-group |
School of Medicine |
|
pubs.publication-status |
Published |
|
pubs.volume |
9 |
|